BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Toronto Dominion Bank

Toronto Dominion Bank grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRNGet Rating) by 4.4% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 41,066 shares of the biotechnology company’s stock after acquiring an additional 1,749 shares during the quarter. Toronto Dominion Bank’s holdings in BioMarin Pharmaceutical were worth $3,403,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Steward Partners Investment Advisory LLC raised its holdings in BioMarin Pharmaceutical by 325.5% during the first quarter. Steward Partners Investment Advisory LLC now owns 2,451 shares of the biotechnology company’s stock worth $189,000 after purchasing an additional 1,875 shares in the last quarter. Arizona State Retirement System raised its stake in BioMarin Pharmaceutical by 2.4% during the 1st quarter. Arizona State Retirement System now owns 51,105 shares of the biotechnology company’s stock worth $3,940,000 after acquiring an additional 1,184 shares in the last quarter. abrdn plc lifted its position in BioMarin Pharmaceutical by 14.1% in the first quarter. abrdn plc now owns 23,058 shares of the biotechnology company’s stock valued at $1,790,000 after acquiring an additional 2,849 shares during the last quarter. Banque Pictet & Cie SA acquired a new position in BioMarin Pharmaceutical in the first quarter valued at $2,230,000. Finally, Clearstead Advisors LLC grew its holdings in shares of BioMarin Pharmaceutical by 10,036.1% during the first quarter. Clearstead Advisors LLC now owns 3,649 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 3,613 shares during the last quarter. Institutional investors and hedge funds own 94.84% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BMRN. StockNews.com started coverage on BioMarin Pharmaceutical in a report on Wednesday, October 12th. They issued a “buy” rating for the company. Wedbush reissued a “neutral” rating and issued a $74.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday, September 13th. SVB Leerink lifted their target price on shares of BioMarin Pharmaceutical from $115.00 to $122.00 and gave the company an “outperform” rating in a report on Thursday, August 4th. Piper Sandler increased their price target on shares of BioMarin Pharmaceutical from $125.00 to $128.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 9th. Finally, Stifel Nicolaus lifted their price objective on shares of BioMarin Pharmaceutical to $104.00 in a research note on Wednesday, September 28th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $111.07.

Insider Transactions at BioMarin Pharmaceutical

In related news, EVP Jeffrey Robert Ajer sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, November 2nd. The shares were sold at an average price of $86.12, for a total value of $258,360.00. Following the completion of the sale, the executive vice president now owns 41,088 shares in the company, valued at $3,538,498.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 4,000 shares of the business’s stock in a transaction on Friday, October 14th. The stock was sold at an average price of $89.89, for a total transaction of $359,560.00. Following the sale, the chief executive officer now directly owns 324,324 shares in the company, valued at $29,153,484.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Jeffrey Robert Ajer sold 3,000 shares of the firm’s stock in a transaction on Wednesday, November 2nd. The shares were sold at an average price of $86.12, for a total value of $258,360.00. Following the completion of the transaction, the executive vice president now owns 41,088 shares of the company’s stock, valued at approximately $3,538,498.56. The disclosure for this sale can be found here. Insiders have sold a total of 8,500 shares of company stock valued at $747,745 in the last ninety days. 1.75% of the stock is currently owned by company insiders.

BioMarin Pharmaceutical Stock Performance

NASDAQ BMRN opened at $97.79 on Friday. The stock has a market capitalization of $18.14 billion, a price-to-earnings ratio of 232.83, a PEG ratio of 2.06 and a beta of 0.34. The business’s 50 day moving average is $86.93 and its two-hundred day moving average is $85.62. BioMarin Pharmaceutical Inc. has a 12-month low of $70.73 and a 12-month high of $99.74. The company has a current ratio of 5.15, a quick ratio of 3.54 and a debt-to-equity ratio of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Rating) last announced its quarterly earnings data on Wednesday, October 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). BioMarin Pharmaceutical had a return on equity of 2.50% and a net margin of 4.18%. The business had revenue of $505.30 million for the quarter, compared to analyst estimates of $516.03 million. During the same period in the prior year, the company earned ($0.03) EPS. The company’s revenue was up 23.6% on a year-over-year basis. Research analysts expect that BioMarin Pharmaceutical Inc. will post 0.88 EPS for the current year.

About BioMarin Pharmaceutical

(Get Rating)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Stories

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.